January 25, 2021
Newsroom
Displaying 111–120 of 124
January 11, 2021
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
January 11, 2021
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
January 4, 2021
Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 8, 2020
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 4, 2020
Seer Announces Pricing of Initial Public Offering
September 15, 2020
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
September 15, 2020
Seer Appoints Catherine Friedman to its Board of Directors
July 22, 2020
Seer Announces $55M Financing Led by Fidelity Management and Research Company
July 22, 2020
Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics
No results found.
Starting your proteomics research is effortless
Connect with an expert to discuss which path to the full proteome is right for you.
-
Bring the Proteograph Product Suite in-house
-
Run a project with
Seer Technology
Access Center -
Conduct a project with
a Seer service provider
or Center of Excellence